| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Departments of Orthopaedics and Rehabilitation [M. M. S., Z. L., Z. Z., H. J. D.] and Cellular and Molecular Physiology [H. J. D.] and Jake Gittlen Cancer Research Institute [C. R. W., D. R. W.], The Pennsylvania State University College of Medicine, The Milton S. Hershey Medical Center, Hershey, Pennsylvania 17033, and Department of Urology, University of Virginia, Charlottesville, Virginia 22908 [M. J. S.]
| ABSTRACT |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
| Materials and Methods |
|---|
|
|
|---|
Assessment of GJIC.
To corroborate GJIC assays, two complimentary techniques were used, as described previously (10)
. Homospecific and heterospecific GJIC were functionally assessed using double labeling fluorescent dye transfer assays (11)
and direct cell injections (10)
. Homospecific coupling was assessed for the three tumorigenic cell lines: MDA 435, 435pVC, and 435-BRMS1. Heterospecific coupling was assessed among the three tumorigenic cell lines in all possible combinations, as well as with the nontumorigenic, nonmetastatic human breast line, HS578Bst.
For double labeling assays, "acceptor" cells were plated at a density of 4 x 104 cells/cm2 to round (25-mm) glass coverslips placed previously in round (35-mm) polystyrene Petri dishes. Cells were allowed to reach 90% confluence at 37°C in a humidified CO2 incubator over a period of 2448 h. Simultaneously, "donor" cells were plated at a density of 4 x 104 cells/cm2 in 35-mm tissue culture dishes and maintained at 37°C over the same time period. GJIC was quantified as described previously (12) . Briefly, donor cells were labeled with a fluorescent dye mixture containing calcein AM (Molecular Probes, Eugene, Oregon) and 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate (Molecular Probes), detached, centrifuged, resuspended in fresh growth medium, and counted using a hemacytometer. Double-labeled donor cells were then dropped onto confluent monolayers of unlabeled acceptor cells at a ratio of approximately 1:500 (labeled:unlabeled) cells and incubated for 90 min at 37°C. After incubation, the coverslips were removed from the dishes, washed twice with room temperature PBS, and inverted onto clean, glass microscope slides and evaluated using a Nikon epifluorescence microscope (Nikon EFD-3; Optical Apparatus Co., Ardmore, PA). Calcein, because of its small molecular size (Mr 994,870), diffuses to neighboring cells via GJIC. The fluorescent dye, 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate, intercalates within cell membranes and does not transfer to neighboring cells via GJIC but is used to visualize the donor cell.
For direct cell injections, cells were plated at a density of 3.5 x 104 cells/cm2 on round (25-mm) glass coverslips in tissue culture dishes and examined at 90% confluence. Cells were washed twice with room temperature PBS and sandwiched in a metal and nylon well affixed to the fluorescent microscope and submerged in room temperature PBS throughout the duration of the experiment. Individual cells were impaled with glass micropipettes that had been backfilled with a fluorescent dye mixture of Lucifer yellow (Molecular Probes) dissolved in lithium chloride. Cells were impaled 3 min, the pipette was removed, and dye transfer was monitored for an additional 2 min. In preliminary experiments, it was found that 435-BRMS1 cells did not adhere firmly to glass substrates. Therefore, in an attempt to optimize cell attachment, we plated 435-BRMS1 cells onto coverslips coated with collagen type I (10 µg/cm2) and type II (.5 mg/ml), fibronectin (10 µg/cm2), Matrigel (1 mg/ml), Cell-tak (1 mg/ml), poly-D-lysine (5 µg/cm2), and poly-L-lysine (5 µg/cm2) purchased from Becton Dickinson (Bedford, MA). We found that poly-D-lysine coating provided optimal conditions for our experiments; therefore, all experiments reported are from cells plated on poly-D-lysine.
Northern Blot Analysis of Cx mRNA Expression.
Steady-state mRNA levels of the gap junction proteins Cx26, Cx32, Cx43, Cx45, and Cx46 were quantified by Northern blot analysis for all four cell lines examined. Cells were plated at a density of 2 x 104 cells/cm2 in 100-mm tissue culture dishes and cultured to confluence, and total RNA was isolated as described (11)
. Briefly, total RNA (20 µg), as determined by absorption at 260 nm, was subjected to electrophoresis on a 1% agarose formaldehyde gel. The gels were then capillary blotted with 100 mM sodium phosphate onto membranes (Gene Screen Hybridization Transfer Membrane; DuPont NEN) and prehybridized for 15 min at 55°C in 1% BSA, 350 mM sodium phosphate, 7% SDS, and 30% (v/v) deionized formamide and followed by hybridization overnight in the same solution with [
-32P]dCTP-labeled probes for the 1.3-kb coding region of Cx43 cDNA, the entire 1.2-kb coding region of Cx45 cDNA, an EcoRI fragment of rat Cx46 cDNA, a 1.1-kb HincII-Bst fragment of Cx26 cDNA, a full-length 1.5-kb cDNA for Cx32 cDNA, or a 1.4-kb PstI fragment of rat glyceraldehyde 3-phosphate dehydrogenase cDNA. The blots were washed once in 150 mM sodium phosphate and 0.1% SDS at room temperature, followed by two washings at 55°C.
| Results |
|---|
|
|
|---|
|
Expression of Cx mRNA.
We did not detect mRNA for Cx26, Cx45, or Cx46 (data not shown) in any of the cell lines examined. However, Cx43 mRNA was highly expressed in HS578Bst cells and 435-BRMS1 cells, albeit less abundantly in the latter. On the other hand, Cx43 mRNA was not detected in MDA 435 or 435pVC cells (Fig. 2)
. Interestingly, although Cx32 mRNA was highly expressed in 435 and 435pVC, it was not detected in HS578Bst and 435-BRMS1 cells (Fig. 3)
. These findings were consistent with three separate experiments.
|
|
| Discussion |
|---|
|
|
|---|
Cx43 is the predominant gap junction protein in normal breast epithelial tissue (13) , but the expression of Cx26 in normal breast epithelial tissue is less clear. Some groups have failed to detect Cx26 in normal mammary tissue, whereas other groups have (14 , 15) . The expression of other Cxs, including Cx32, has not been reported in human breast tissue, but in mice Cx26 and Cx32 have been reported in breast tissue during pregnancy and lactation, respectively (16) .
In the HS578Bst breast epithelium-derived cells, Cx43, but not Cx26 or Cx32, was expressed. On the other hand, metastatic MDA 435 cells expressed neither Cx26 nor Cx43, consistent with the loss of Cx43 expression reported in neoplastic breast tissue (15) , but did express Cx32. Restoring BRMS1 expression results in reestablishment of GJIC but only partly restored Cx43 expression. This suggests the possibility of novel Cxs in 435-BRMS1 cells or, more likely, that a relatively low level of Cx43 expression is sufficient for establishing detectable GJIC. A more striking finding was that although metastatic MDA 435 cells expressed Cx32, metastasis-suppressed 435-BRMS1 cells did not. To our knowledge, Cx32 has not been thoroughly examined in tumorigenic and metastatic breast cancer cells. To date, the only study examining Cx32 in neoplastic tissue failed to detect it in breast carcinoma (15) . Our data suggest that re-expression of the metastasis-suppressor gene BRMS1 returns the Cx expression profile from that of a metastatic cell (Cx32 but not Cx43) to that more similar to a normal breast epithelial cell (Cx43 but not Cx32). Furthermore, although BRMS1 expression restores, at least in part, Cx43 mRNA expression, it may inhibit Cx32 mRNA expression. At minimum, these data imply that the composition of gap junctions contributes to metastatic propensity. It is also possible, although more extensive studies are required, that Cx32 expression contributes to breast cancer cell metastatic potential.
The mechanism by which altered Cx expression and GJIC might contribute to metastasis is unclear. One possibility is that deficient heterospecific GJIC between cancer cells and normal breast epithelial cells contributes to detachment of the malignant cells from the primary tumor. This concept is supported by studies showing a relationship between E-cadherin, a cell-cell adhesion molecule that is down-regulated in many tumors (17) , and gap junction expression and function (18) . However, none of the MDA 435 variants express E-cadherin (7) , suggesting that E-cadherin may contribute to tumorigenesis but not metastatic potential. This does not preclude the possibility that altered Cx expression and GJIC may regulate other cell adhesion molecules that could contribute to the detachment of malignant cells from the primary tumor.
Another mechanism by which altered Cx expression and GJIC might contribute to metastatic potential is by facilitating arrest on, or colonization of, the secondary tumor environment. For instance, GJIC has been demonstrated between metastatic tumor cells and vascular endothelium (19) and is directly related to metastatic potential (20) . Recently, Ito et al. (3) demonstrated that B16-BL6 melanoma cells, which are metastatic after s.c. injection, expressed Cx26 and displayed GJIC with endothelial cells. However, B16-F10 melanoma cells, which did not metastasize after s.c. injection in their hands, did not express Cx26, nor did they establish GJIC with endothelial cells. Transfection with wild-type Cx26 made F10 cells as competent to communicate with endothelial cells as B16-BL6 cells. Conversely, transfection with a dominant-negative form of Cx26 rendered B16-BL6 cells deficient in GJIC and less metastatic. Taken together, these results suggest that heterospecific GJIC between tumor cells and endothelial cells, or other cells in the secondary tumor environment, may contribute to the metastatic potential of malignant cells. Future studies will address these possibilities.
In summary, the experiments presented here demonstrate two things: (a) they show that restoration of BRMS1 expression in MDA 435 cells results in concomitant reduction in metastatic efficiency and restoration of GJIC; and (b) BRMS1 expression alters Cx expression in the tumor cells. Together these findings imply that BRMS1 is acting by a novel mechanism to inhibit metastasis, and that GJIC mediated by specific Cxs may be a major determinant of metastatic potential in human breast cancer.
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
1 This work was supported by Grants AG13087 and CA87728 from the NIH, Grant BC995879 from the United States Army, and a grant from the National Foundation for Cancer Research. ![]()
2 To whom requests for reprints should be addressed, at Musculoskeletal Research Laboratory, Department of Orthopaedics and Rehabilitation, The Pennsylvania State University College of Medicine, P. O. Box 850, 500 University Drive, Hershey, PA 17033. Phone: (717) 531-4818; Fax: (717) 531-7583. ![]()
3 The abbreviations used are: GJIC, gap junctional intercellular communication; Cx, connexin; BRMS1, breast metastasis suppressor 1. ![]()
Received 11/ 2/00. Accepted 1/11/01.
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
D. R. Hurst, Y. Xie, K. S. Vaidya, A. Mehta, B. P. Moore, M. A. Accavitti-Loper, R. S. Samant, R. Saxena, A. C. Silveira, and D. R. Welch Alterations of BRMS1-ARID4A Interaction Modify Gene Expression but Still Suppress Metastasis in Human Breast Cancer Cells J. Biol. Chem., March 21, 2008; 283(12): 7438 - 7444. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. Phadke, K. S. Vaidya, K. T. Nash, D. R. Hurst, and D. R. Welch BRMS1 Suppresses Breast Cancer Experimental Metastasis to Multiple Organs by Inhibiting Several Steps of the Metastatic Process Am. J. Pathol., March 1, 2008; 172(3): 809 - 817. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M.J. Conklin, J. F. Bechberger, D. MacFabe, N. Guthrie, E. M. Kurowska, and C. C. Naus Genistein and quercetin increase connexin43 and suppress growth of breast cancer cells Carcinogenesis, January 1, 2007; 28(1): 93 - 100. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Liu, P. W. Smith, and D. R. Jones Breast Cancer Metastasis Suppressor 1 Functions as a Corepressor by Enhancing Histone Deacetylase 1-Mediated Deacetylation of RelA/p65 and Promoting Apoptosis Mol. Cell. Biol., December 1, 2006; 26(23): 8683 - 8696. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Kalra, Q. Shao, H. Qin, T. Thomas, M. A. Alaoui-Jamali, and D. W. Laird Cx26 inhibits breast MDA-MB-435 cell tumorigenic properties by a gap junctional intercellular communication-independent mechanism Carcinogenesis, December 1, 2006; 27(12): 2528 - 2537. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Zhang, H. Yamashita, T. Toyama, Y. Yamamoto, T. Kawasoe, and H. Iwase Reduced expression of the breast cancer metastasis suppressor 1 mRNA is correlated with poor progress in breast cancer. Clin. Cancer Res., November 1, 2006; 12(21): 6410 - 6414. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Cher, D. A. Towler, S. Rafii, D. Rowley, H. J. Donahue, E. Keller, M. Herlyn, E. A. Cho, and L. W.K. Chung Cancer Interaction with the Bone Microenvironment: A Workshop of the National Institutes of Health Tumor Microenvironment Study Section Am. J. Pathol., May 1, 2006; 168(5): 1405 - 1412. [Full Text] [PDF] |
||||
![]() |
L. N. Torres, J. M. Matera, C. H. Vasconcellos, J. L. Avanzo, F. J. Hernandez-Blazquez, and M. L. Z. Dagli Expression of Connexins 26 and 43 in Canine Hyperplastic and Neoplastic Mammary Glands Vet. Pathol., September 1, 2005; 42(5): 633 - 641. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. S. Steeg PERSPECTIVES ON CLASSIC ARTICLES: Metastasis Suppressor Genes J Natl Cancer Inst, March 17, 2004; 96(6): E4 - E4. [Full Text] |
||||
![]() |
W. J. Meehan, R. S. Samant, J. E. Hopper, M. J. Carrozza, L. A. Shevde, J. L. Workman, K. A. Eckert, M. F. Verderame, and D. R. Welch Breast Cancer Metastasis Suppressor 1 (BRMS1) Forms Complexes with Retinoblastoma-binding Protein 1 (RBP1) and the mSin3 Histone Deacetylase Complex and Represses Transcription J. Biol. Chem., January 9, 2004; 279(2): 1562 - 1569. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. C. Park, R. L. Henshall-Powell, A. C. Erickson, R. Talhouk, B. Parvin, M. J. Bissell, and M. H. Barcellos-Hoff Ionizing radiation induces heritable disruption of epithelial cell interactions PNAS, September 16, 2003; 100(19): 10728 - 10733. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-T. Chen, Y.-W. Cheng, M.-C. Chou, T. Sen-Lin, W.-W. Lai, W. L. Ho, and H. Lee The Correlation between Aberrant Connexin 43 mRNA Expression Induced by Promoter Methylation and Nodal Micrometastasis in Non-Small Cell Lung Cancer Clin. Cancer Res., September 15, 2003; 9(11): 4200 - 4204. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Mograbi, E. Corcelle, N. Defamie, M. Samson, M. Nebout, D. Segretain, P. Fenichel, and G. Pointis Aberrant Connexin 43 endocytosis by the carcinogen lindane involves activation of the ERK/mitogen-activated protein kinase pathway Carcinogenesis, August 1, 2003; 24(8): 1415 - 1423. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Mareel and A. Leroy Clinical, Cellular, and Molecular Aspects of Cancer Invasion Physiol Rev, April 1, 2003; 83(2): 337 - 376. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Qin, Q. Shao, H. Curtis, J. Galipeau, D. J. Belliveau, T. Wang, M. A. Alaoui-Jamali, and D. W. Laird Retroviral Delivery of Connexin Genes to Human Breast Tumor Cells Inhibits in Vivo Tumor Growth by a Mechanism That Is Independent of Significant Gap Junctional Intercellular Communication J. Biol. Chem., August 2, 2002; 277(32): 29132 - 29138. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. W. Hunter, K. W. Broman, T. L. Voyer, L. Lukes, D. Cozma, M. T. Debies, J. Rouse, and D. R. Welch Predisposition to Efficient Mammary Tumor Metastatic Progression Is Linked to the Breast Cancer Metastasis Suppressor Gene Brms1 Cancer Res., December 1, 2001; 61(24): 8866 - 8872. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Subauste, B. List, X. Guan, K. M. Hahn, R. Lerner, and N. B. Gilula A Catalytic Antibody Produces Fluorescent Tracers of Gap Junction Communication in Living Cells J. Biol. Chem., December 21, 2001; 276(52): 49164 - 49168. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |